Recent Updates
Recently added Catalysts
PLRX

Pliant Therapeutics to Participate in the BTIG Biotechnology Conference

Key Takeaway: SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced its participation in the 2021 BT
Price reaction · baseline $21.8 (2021-08-02 close) · hit after-hours · clean, no other PLRX news in the window
day 0 close · peak
-1%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+47%
120-day peak, hindsight
Typical move
1.5%
average across 6 past catalysts
Cash runway
~37 mo
Minimal dilution risk
Lead asset
PLN-101095
Phase 1 · Advanced or Metastatic Solid Tumor

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced its participation in the 2021 BTIG Virtual Biotechnology Conference to be held August 9 – 10, 2021.
Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in a fireside chat on Tuesday, August 10, 2021, at 3:30 p.m. EST / 12:30 p.m. PST and, along with members of Pliant’s senior management team, will conduct one-on-one meetings with members of the investment community.
About Pliant Therapeutics, Inc.
Investor and Media Contact:
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
Last updated: Aug 3, 2021